PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer
- PMID: 27007578
- DOI: 10.1056/NEJMoa1514493
PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer
Abstract
Background: The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate.
Methods: In this prospective, randomized, controlled trial, we assessed the noninferiority of positron-emission tomography-computed tomography (PET-CT)-guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only if PET-CT showed an incomplete or equivocal response) to planned neck dissection in patients with stage N2 or N3 disease. The primary end point was overall survival.
Results: From 2007 through 2012, we recruited 564 patients (282 patients in the planned-surgery group and 282 patients in the surveillance group) from 37 centers in the United Kingdom. Among these patients, 17% had nodal stage N2a disease and 61% had stage N2b disease. A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that stained positive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer. The median follow-up was 36 months. PET-CT-guided surveillance resulted in fewer neck dissections than did planned dissection surgery (54 vs. 221); rates of surgical complications were similar in the two groups (42% and 38%, respectively). The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in the surveillance group and 81.5% (95% CI, 76.9 to 86.3) in the planned-surgery group. The hazard ratio for death slightly favored PET-CT-guided surveillance and indicated noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P=0.004). There was no significant difference between the groups with respect to p16 expression. Quality of life was similar in the two groups. PET-CT-guided surveillance, as compared with neck dissection, resulted in savings of £1,492 (approximately $2,190 in U.S. dollars) per person over the duration of the trial.
Conclusions: Survival was similar among patients who underwent PET-CT-guided surveillance and those who underwent planned neck dissection, but surveillance resulted in considerably fewer operations and it was more cost-effective. (Funded by the National Institute for Health Research Health Technology Assessment Programme and Cancer Research UK; PET-NECK Current Controlled Trials number, ISRCTN13735240.).
Comment in
-
Management of Advanced Head and Neck Cancer.N Engl J Med. 2016 Aug 4;375(5):492-3. doi: 10.1056/NEJMc1606211. N Engl J Med. 2016. PMID: 27518680 No abstract available.
-
Management of Advanced Head and Neck Cancer.N Engl J Med. 2016 Aug 4;375(5):491-2. doi: 10.1056/NEJMc1606211. N Engl J Med. 2016. PMID: 27518681 No abstract available.
-
Management of Advanced Head and Neck Cancer.N Engl J Med. 2016 Aug 4;375(5):492. doi: 10.1056/NEJMc1606211. N Engl J Med. 2016. PMID: 27518682 No abstract available.
-
Improving Head and Neck Cancer Outcomes: Technology, Used Wisely.Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):489-92. doi: 10.1016/j.ijrobp.2016.04.021. Int J Radiat Oncol Biol Phys. 2016. PMID: 27681744 No abstract available.
Similar articles
-
PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.Health Technol Assess. 2017 Apr;21(17):1-122. doi: 10.3310/hta21170. Health Technol Assess. 2017. PMID: 28409743 Free PMC article. Clinical Trial.
-
Revisiting the role of positron-emission tomography/computed tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer.Laryngoscope. 2009 Nov;119(11):2150-5. doi: 10.1002/lary.20523. Laryngoscope. 2009. PMID: 19544378
-
N2 disease in patients with head and neck squamous cell cancer treated with chemoradiotherapy: is there a role for posttreatment neck dissection?Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1112-8. doi: 10.1001/archoto.2009.148. Arch Otolaryngol Head Neck Surg. 2009. PMID: 19917924
-
Lymph node positive head and neck carcinoma after curative radiochemotherapy: a long lasting debate on elective post-therapeutic neck dissections comes to a conclusion.Cancer Radiother. 2013 Jul-Aug;17(4):323-31. doi: 10.1016/j.canrad.2013.01.018. Epub 2013 May 23. Cancer Radiother. 2013. PMID: 23706533 Review.
-
Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all?Head Neck. 2006 Feb;28(2):166-75. doi: 10.1002/hed.20302. Head Neck. 2006. PMID: 16240327 Review.
Cited by
-
The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma.Medicina (Kaunas). 2021 Apr 23;57(5):407. doi: 10.3390/medicina57050407. Medicina (Kaunas). 2021. PMID: 33922457 Free PMC article.
-
PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1749-52. doi: 10.1007/s00259-016-3414-5. Epub 2016 May 13. Eur J Nucl Med Mol Imaging. 2016. PMID: 27178271 Free PMC article. No abstract available.
-
Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.Br J Radiol. 2016 Nov;89(1067):20160217. doi: 10.1259/bjr.20160217. Epub 2016 Aug 2. Br J Radiol. 2016. PMID: 27416996 Free PMC article. Review.
-
Evolving Treatment Paradigms for Oropharyngeal Squamous Cell Carcinoma.J Glob Oncol. 2018 Sep;4:1-9. doi: 10.1200/JGO.2016.006304. Epub 2016 Nov 9. J Glob Oncol. 2018. PMID: 30241193 Free PMC article. Review.
-
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database.Radiat Oncol. 2018 Jun 18;13(1):113. doi: 10.1186/s13014-018-1057-3. Radiat Oncol. 2018. PMID: 29914515 Free PMC article.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical